These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 22956222
1. [Immunosuppression in inflammatory bowel disease: When, how and how long?]. Gross V. Dtsch Med Wochenschr; 2012 Sep; 137(37):1803-5. PubMed ID: 22956222 [Abstract] [Full Text] [Related]
2. [Biological therapy as treatment of inflammatory bowel diseases]. Agnholt J. Ugeskr Laeger; 2008 Jun 09; 170(24):2152-6. PubMed ID: 18565302 [Abstract] [Full Text] [Related]
3. Immunosuppression in inflammatory bowel disease: traditional, biological or both? Van Assche G, Vermeire S, Rutgeerts P. Curr Opin Gastroenterol; 2009 Jul 09; 25(4):323-8. PubMed ID: 19417645 [Abstract] [Full Text] [Related]
4. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases]. Dejaco C, Gasché C, Reinisch W, Moser G, Novacek G, Tillinger W, Vogelsang H, Gangl A. Wien Klin Wochenschr; 1998 Sep 04; 110(16):579-84. PubMed ID: 9782579 [Abstract] [Full Text] [Related]
5. [Treatment of chronic inflammatory bowel disease based on evidence and according to stage: top down]. Mudter J, Neurath MF. Dtsch Med Wochenschr; 2013 Sep 04; 138(36):1779. PubMed ID: 24002879 [No Abstract] [Full Text] [Related]
6. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. Trinder MW, Lawrance IC. J Gastroenterol Hepatol; 2009 Jul 04; 24(7):1252-7. PubMed ID: 19220669 [Abstract] [Full Text] [Related]
7. [Chronic inflammatory bowel diseases. Earlier transition to immunosuppressive drugs]. Bischoff A. MMW Fortschr Med; 2002 May 02; 144(18):10. PubMed ID: 12422699 [No Abstract] [Full Text] [Related]
8. Therapy of steroid-resistant inflammatory bowel disease. Manz M, Vavricka SR, Wanner R, Lakatos PL, Rogler G, Frei P, Safroneeva E, Schoepfer AM. Digestion; 2012 May 02; 86 Suppl 1():11-5. PubMed ID: 23051721 [Abstract] [Full Text] [Related]
10. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Am J Gastroenterol; 1998 Oct 02; 93(10):1860-6. PubMed ID: 9772045 [Abstract] [Full Text] [Related]
11. Vaccinating patients with inflammatory bowel disease--primum non nocere. Muhammad R, Wong CL, Limdi JK. Scand J Gastroenterol; 2012 Sep 02; 47(8-9):1122-3. PubMed ID: 22554229 [No Abstract] [Full Text] [Related]
12. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Am J Gastroenterol; 2006 May 02; 101(5):1048-56. PubMed ID: 16573777 [Abstract] [Full Text] [Related]
18. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient]. Hellström PM, Schmidt D, Karlén P. Lakartidningen; 2006 May 02; 104(41):2973-6. PubMed ID: 17977308 [No Abstract] [Full Text] [Related]
19. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Aliment Pharmacol Ther; 2009 Aug 02; 30(3):253-64. PubMed ID: 19438424 [Abstract] [Full Text] [Related]